INTRODUCTION

As the population ages, the number of older adults with impaired activities of daily living (ADL) requiring rehabilitation is increasing. Aging is associated with sarcopenia, frailty, and multimorbidity, all of which are widespread medical and geriatric problems that often lead to polypharmacy. Polypharmacy (the use of multiple medications) is a common health concern among older adults and is associated with reduced physical function, low cognitive levels, and malnutrition. Prescribing a large number of drugs can lead to medication-related problems such as potentially inappropriate medication (PIM) use, duplication of therapy, adverse drug effects, drug interactions, poor adherence, unnecessary medication use, and a strain on medical resources.

Pharmacotherapy, or medication management, is important in older patients undergoing rehabilitation because such patients, especially those with frailty and physical disabilities, are susceptible to drug-related functional impairment. Drug-related problems include polypharmacy, potentially inappropriate medications (PIMs), and potential prescription omissions. These problems are associated with adverse drug events such as dysphagia, depression, drowsiness, falls and fractures, incontinence, decreased appetite, and Parkinson’s syndrome, leading to impaired improvement in activities of daily living (ADL), quality of life (QOL), and nutritional status. Moreover, the anticholinergic burden is associated with impaired physical and cognitive functions. Therefore, pharmacist-centered multidisciplinary pharmacotherapy should be performed to maximize rehabilitation outcomes. Pharmacotherapy includes a review of all medications, the assessment of drug-related problems, goal setting, correction of polypharmacy and PIMs, monitoring of drug prescriptions, and reassessment of drug-related problems. The goal of pharmacotherapy in rehabilitation medicine is to optimize drug prescribing and to maximize the improvement of ADL and QOL at patient outcomes.

The role of pharmacists during rehabilitation is to treat patients as part of multidisciplinary teams and as key members of nutritional support teams. In this review, we aim to highlight existing evidence regarding pharmacotherapy in older adults, including drug-related functional impairment and the association between pharmacotherapy and functional, cognitive, and nutritional outcomes among patients undergoing rehabilitation. In addition, we highlight the important role of pharmacists in maximizing improvements in rehabilitation outcomes and minimizing drug-related adverse effects.
for medications mainly used to prevent or treat the complications of acute illness, despite these medications having no documented indication for chronic use. These prescribing practices are associated with significant costs and may have no obvious benefit to patients; however, they may have a significant impact on subsequent rehabilitation outcomes. Indeed, the association of polypharmacy and PIMs have a significant impact on subsequent rehabilitation outcomes among older adults undergoing rehabilitation. Therefore, pharmacist needs to be performed in the rehabilitation medicine environment by a multidisciplinary team of medical professionals led by pharmacists. However, to date, this subject has not been well studied.

In this review, we aim to highlight existing evidence regarding pharmacotherapy in older adults; drug-related functional impairment; and the association between pharmacotherapy and functional, cognitive, and nutritional outcomes among older adults undergoing rehabilitation. Additionally, we highlight the important role of pharmacists in maximizing improvements in rehabilitation outcomes and minimizing drug-related adverse effects. This review will benefit all members of the multidisciplinary teams involved in rehabilitation medicine.

**PHARMACOTHERAPY IN OLDER ADULTS**

**Polypharmacy**

Polypharmacy is classified as a geriatric syndrome and is frequently observed in older adults. This phenomenon is a major concern in relation to adverse health outcomes such as falls, functional impairment, adverse drug reactions, prolonged hospitalization, rehospitalization, poor rehabilitation outcomes, and mortality. Multiple factors positively associated with polypharmacy such as drug–drug interactions, drug–disease interactions, and PIMs may contribute to these adverse outcomes. Adverse drug events (ADEs) caused by interactions or contraindications can be misinterpreted as new symptoms or diagnoses, which may result in new drug prescriptions. This negative spiral of prescribing to treat side effects and interactions, also known as the prescribing cascade, increases the risk of polypharmacy. The risk of prescription cascade increases with an increase in drug–drug interactions and contraindications (drug–disease). Therefore, polypharmacy is an important issue in rehabilitation clinical practice and is considered to be a growing problem.

While polypharmacy is defined as the ingestion of a large number of drugs, it is also used to refer to associated conditions that increase the risk of drug side effects, drug errors, and poor adherence. There is no strict definition of the number of drugs that constitute polypharmacy. A previous report found that the consumption of six or more medications was associated with an increased incidence of adverse drug reactions. However, a recent systematic review found that the occurrence of adverse drug reactions is associated with the intake of 2–11 drugs, and that the risk of adverse drug reactions cannot be determined by the number of drugs alone. Furthermore, as long as the complete list of medications is reviewed and the risk/benefit ratio for each patient has been evaluated, polypharmacy is not problematic per se, and the term “appropriate polypharmacy” is applicable. Therefore, it is necessary to optimize the content of prescriptions not only in terms of the number and type of drugs, but also in terms of safety.

**Potentially Inappropriate Medications**

Drugs with a high risk of ADEs are commonly referred to as inappropriate prescriptions for older adults. Inappropriate prescription practices include both potentially inappropriate medications (PIMs) and potential prescription omissions (PPOs). PIMs are defined as drugs that are associated with more clinical risks (including drug–drug and drug–disease interactions) than benefits. The two most frequently used quality criteria are the Beers criteria and the Screening Tool of Older Persons’ potentially inappropriate Prescriptions (STOPP) criteria. These tools were developed in the United States (US) and Europe; however, because they can be applied in a short time and include many drugs approved in Japan, they are being used in Japan as screening tools for PIMs in older adults. The most frequently prescribed PIMs included vasodilators, benzodiazepines, antidepressants, cardiac medications, and anticoagulants. PIMs are associated with older age, frailty, and polypharmacy. A review of all medications is recommended in older adults, particularly if more than 10 drugs are prescribed in combination; such combination prescriptions increase the likelihood of PIMs.

PIMs are associated with poor outcomes in older adults in clinical practice including rehabilitation medicine. Hyperpolypharmacy (use of >10 drugs) or PIMs in post-acute older adults is associated with a decline in basic ADL. The use of PIMs in patients with hip fractures delays full functional recovery. Increased PIM use during rehabilitation hospitalization is associated with decreased functional improvement in geriatric patients after a stroke. In addition, PIMs are associated with psychological problems,
poor quality of life (QOL), and unplanned readmissions in hospitalized older patients. These findings suggest that PIMs may negatively impact the outcomes of patients undergoing rehabilitation. Furthermore, the use of PIMs in older adults tends to increase after hospitalization, especially in convalescent rehabilitation settings where antipsychotics, antidepressants, and first-generation antihistamines are administered more frequently during hospitalization. Therefore, pharmacists and physicians need to collaborate in a multidisciplinary manner to screen for PIMs and to provide appropriate pharmacotherapy for hospitalized older adults undergoing rehabilitation.

**Potential Prescribing Omissions, or Underuse**

Inappropriate prescribing in older adults includes PIMs and potential prescription omissions (PPOs); a PPO, or the underuse of medication, is defined as “not prescribing a beneficial medicine for which there is a clear clinical indication” and may be related to increasing numbers of hospital admissions and falls, exacerbation of chronic conditions, and the development of secondary diseases. The Screening Tool to Alert to Right Treatment (START criteria) has been developed to identify PPOs in older adults and to encourage physicians to prescribe the correct treatment; START has been validated and its use is recommended in clinical practice. A previous study reported that PPOs were found in nearly half of all community-dwelling older adults, and that the probability of PPOs increased significantly with the number of medications. In older adults, PPOs are more common in patients with cardiovascular disease, hyperlipidemia, osteoporosis, chronic obstructive pulmonary disease, depression, and cancer. It can be assumed that physicians are unwilling to prescribe more drugs to patients with polypharmacy because of the complexity of drug therapy, ADEs, drug–drug interactions, and fear of poor adherence. However, pharmacists and physicians should be cautious in pharmacotherapy, especially in older patients with multimorbidity, because PPOs may be associated with a poor prognosis in these patients.

**Anticholinergic Effects**

The side effects of anticholinergic drugs are not well recognized in older adults. Such effects include headache, drowsiness, dry mouth, hand tremors, unstable movements, falls, blurred vision, and increased anxiety. Anticholinergic drugs can worsen cognitive function, especially in patients with Alzheimer’s disease and other dementias in which central cholinergic neurotransmission has already been compromised. Older adults are at a higher risk of anticholinergic side effects, partly because of deficits in drug metabolism, excretion, and age-related deficits in cholinergic neurotransmission. Anticholinergic drugs are commonly prescribed for older adults: 23% of community-dwelling older adults and 60% of nursing home residents reportedly take anticholinergic medications, and 34% of nursing home residents and 13% of community-dwelling older adults reportedly take two or more anticholinergic medications.

The anticholinergic burden is independently associated with impaired physical function and ADL, e.g., gait and the ability to stand up from a chair. However, the extent to which this association can be attributed to anticholinergic effects versus that to related diseases and fraility is unclear. To date, there is limited evidence to indicate that reducing the burden of anticholinergic effects leads to improved function, engagement in rehabilitation, or improved habitual physical activity.

The total anticholinergic load (cumulative potential load) is an important consideration when prescribing anticholinergic drugs. The anticholinergic risk scale (ARS) was developed to provide a score for the strength of each anticholinergic medication. Drugs with high ARS scores have strong anticholinergic effects and are associated with poor prognostic outcomes in rehabilitation such as lower cognitive levels, poorer physical function, and a lower rate of home discharge.

**Dysphagia**

Dysphagia is associated with negative outcomes such as the development of pneumonia and malnutrition in rehabilitated patients. Aging, diseases such as stroke and neurological disorders, and medications can cause dysphagia. The swallowing process is divided into the antecedent, preparatory, oropharyngeal, pharyngeal, and esophageal phases, and some medications have negative effects on all these phases. Drowsiness, decreased level of consciousness, decreased cognitive function, decreased saliva secretion, inadequate food mass formation due to xerostomia, decreased swallowing clearance, and extrapyramidal symptoms are the main causes of drug-induced dysphagia. In particular, drugs with anticholinergic effects exert an inhibitory effect at the level of the central nervous system and also cause dry mouth due to decreased salivary secretion. The ARS score is associated with the development of aspiration pneumonia in

---

*Copyright © 2022 The Japanese Association of Rehabilitation Medicine*
Depression and Drowsiness

Depression and drowsiness are factors that inhibit “participation” in rehabilitation and decrease the likelihood of maximizing rehabilitation outcomes. Depression is commonly a post-stroke complication but may also be caused by medications. Psychiatric side effects such as insomnia and depression occur early during the initiation of corticosteroid therapy. Central sympathetic inhibitors (central alpha 2 agonists), beta blockers, and histamine H2 receptor antagonists can also induce depression.

Drugs that cause drowsiness include sedatives, antipsychotics, antidepressants, opioids, and antiepileptic drugs. Sedative drugs and antipsychotics are commonly used in rehabilitation patients for the treatment of insomnia, delirium, and peripheral symptoms of dementia and can cause oversedation and somnolence. Drugs with anticholinergic effects also induce drowsiness due to their central depressant effects. The reduction or discontinuation of antipsychotics (for schizophrenia and other psychiatric disorders) and antiepileptic drugs (for epilepsy) may be difficult because of the therapeutic needs of the underlying disease. In such cases, rehabilitation should be performed with caution, taking into account all the possible side effects.

Antidepressants may be useful for treating depressive symptoms. Tricyclic antidepressants have potent antidepressant effects; however, they should be administered cautiously to older patients because of their strong anticholinergic effects. Selective serotonin reuptake inhibitors (SSRIs) are associated with a risk of falls and gastrointestinal bleeding, and caution is required while prescribing these drugs to high-risk patients. Antidepressants are associated with drowsiness, and the risks and benefits of treating depression and drowsiness should be carefully considered.

Falls and Fractures

Falls occur at least once a year in 29% of community-dwelling older adults aged ≥65 years (rate of 0.67 falls per person per year). It is estimated that 10% of older adults fall at least twice a year, and patients who visit the clinic regularly are more likely to belong to this high-risk group because they have more diseases and disabilities that increase their risk of falling. Serious complications such as fractures, joint dislocations, sprains, and concussions occur in approximately 10% of falls. Among these complications, hip fracture is one of the main factors causing older patients to become bedridden and to need nursing care; hip fracture accounts for the majority of conditions that require convalescent rehabilitation in Japan.

Factors associated with falls include sarcopenia, impaired balance, gait disturbance, visual impairment, orthostatic hypotension, decreased ADL, decreased instrumental ADL, and medications. Medication issues that increase the risk of falls include polypharmacy as well as the prescription of antipsychotics, antidepressants, benzodiazepines, and loop diuretics. Medication-related side effects such as sedation, impaired balance, decreased responsiveness, dizziness, syncope, postural hypotension, and drug-induced parkinsonism have been identified as potential causes of falls.

Constipation and Fecal Incontinence

Constipation, diarrhea, and fecal incontinence are commonly observed geriatric syndromes in rehabilitation patients, and defecation control is one of the most important tasks for healthcare providers and caregivers. Anticholinergic drugs are the most important among the many drugs that cause constipation and should be prescribed as little as possible to older adults owing to their side effects; if needed, these drugs should be used with caution. Magnesium oxide has been widely used as a laxative and is considered to be convenient, inexpensive, and relatively safe to administer. However, while prescribing magnesium oxide, optimal dosing, serum concentrations, drug–drug interactions, and potential side effects such as hypermagnesemia need to be...
considered; this is especially of consequence in older adults and in patients with renal impairment. Because older patients are prone to dehydration, if diarrhea persists, the dose of the causative drug should be reduced or discontinued; if necessary, intravenous fluids should be used to stabilize circulation and correct electrolyte abnormalities. In older patients and those with polypharmacy, it is important to check for new and regular prescriptions to avoid drug-induced urinary incontinence. Anticholinergic side effects that can impair cognition and reaction time, which in turn can impair the ability to participate in rehabilitation. Therefore, it is important to address urinary incontinence in rehabilitation patients through multidisciplinary discussions; it is also necessary to share information among physicians and pharmacists through a drug management summary at the time of discharge from the rehabilitation ward or hospital.

**Dysuria and Urinary Incontinence**

Dysuria and urinary incontinence are common and often undertreated conditions that impair the QOL of older adults. These conditions are categorized as disorders of urine storage and discharge. Drug-induced dysuria and urinary incontinence can be caused by various classes of drugs including cholinergic agonists, alpha-adrenoceptor blockers, anticholinergics, cold remedies, and antihistamines. In older patients and those with polypharmacy, it is important to check for new and regular prescriptions to avoid drug-induced urinary incontinence. Indeed, urinary incontinence is a predictor of poor rehabilitation outcomes and may contribute to the need for institutional care for many patients. Conversely, many medications used for urinary incontinence have anticholinergic side effects that can impair cognition and reaction time, which in turn can impair the ability to participate in rehabilitation. Therefore, it is important to address urinary incontinence in rehabilitation patients through multidisciplinary discussions; it is also necessary to share information among physicians and pharmacists through a drug management summary at the time of discharge from the rehabilitation ward or hospital.

**Anorexia**

Anorexia causes malnutrition and sarcopenia in patients undergoing rehabilitation and interferes with the improvement of physical function. Anorexia is caused by dysfunctions of the oral and gastrointestinal tracts, central nervous system issues that can lead to abnormal food perception, and decreased general durability and persistence. The causes of drug-induced anorexia vary, and include dry mouth, taste disorders, peptic ulcers, nausea, constipation, diarrhea, cognitive decline, and drowsiness. Anticholinergic drugs induce constipation, dry mouth, and the suppression of gastrointestinal motility. Nonsteroidal anti-inflammatory drugs and bisphosphonates may cause peptic ulcers. Opioids cause central nausea due to direct stimulation of the chemoreceptor trigger zone in the medulla oblongata, nausea and constipation due to inhibition of gastrointestinal peristalsis, and increased anal sphincter tone. Digitalis, an inotropic drug, is likely to cause gastrointestinal symptoms in the early stages of the therapy. Biguanides should be prescribed with caution in patients with impaired renal function or dehydration because of the risk of nausea, vomiting, and diarrhea due to lactic acidosis. Anti-cancer drugs cause anorexia, nausea, and vomiting due to damage to the gastrointestinal mucosa and stimulation of the vomiting center. Hypercalcemia caused by active vitamin D3 preparations used in the treatment of osteoporosis and hypermagnesemia caused by magnesium preparations used as laxatives and antacids lead to nausea and anorexia. Some drugs may improve anorexia. Antipsychotic drugs such as sulpiride promote gastrointestinal motility owing to their antidopaminergic effects, leading to increased nutrient intake. However, caution should always be exercised as continuous use of these drugs may cause extrapyramidal symptoms. Mirtazapine, a noradrenergic and serotonergic antidepressant, increases appetite. The Chinese herbal medicine Rikkunshito suppresses gastric evacuation, improves upper gastrointestinal symptoms, and increases ghrelin secretion (which is an appetite stimulant). Hochuekkito and Ninjin Yoeito (herbal medicines) are also effective in improving appetite.

**Anemia**

Severe anemia causes fatigue and breathlessness; this condition reduces activity as well as the ability to participate in rehabilitation. Low baseline hemoglobin levels are associated with sarcopenia, poorer recovery of physical function, and dysphagia in patients undergoing rehabilitation after stroke. Furthermore, improved hemoglobin levels are positively associated with functional recovery and a shorter hospital stay in stroke patients with anemia. Anemia should be assessed as a prognostic indicator at baseline and treated appropriately to maximize patient outcomes. Correction of the underlying disease (e.g., peptic ulcer) is important for treating anemia, and supplementation with nutrients (e.g., iron and vitamin B12) is necessary. Many older adults and those with reduced mobility have mild chronic anemia; however, there is little evidence that correction with iron is effective. Oral iron preparations have no significant effect on anemia and hemoglobin levels (a recent meta-analysis found an average increase of 0.35 g/dL), can cause significant constipation and nausea, and are ineffective in cases of anemia associated with chronic disease.
Parkinson Syndrome

Parkinsonism caused by medication usually develops in 60% of patients within 1 month and 90% within 3 months of starting antipsychotic treatment. Rapid progression within a few days to a few weeks is a characteristic feature. Factors such as age, female sex, amount of drug used, and treatment duration are also associated with the development of adverse reactions.102) A detailed evaluation of the history of antipsychotic treatment is warranted when the progression of symptoms is rapid.102) Because drug-induced parkinsonism is a side effect that tends to persist for a long time, it is important to detect and treat this side effect at an early stage. Prolonged symptoms may result in head trauma due to falls, bone fractures, and cognitive decline, which may interfere with daily life and rehabilitation.103)

Activities of Daily Living

Recently, polypharmacy and PIMs have attracted considerable attention in rehabilitation medicine. Among patients aged ≥65 years undergoing convalescent rehabilitation after stroke, approximately 42% were taking six or more medications at the time of admission and thereby exhibited polypharmacy.104) Approximately 58% of patients with polypharmacy were diagnosed with sarcopenia. Among 144 stroke patients with chronic kidney disease admitted to a convalescent rehabilitation ward, 48 (33.3%) exhibited polypharmacy and took six or more drugs; the improvement in ADL was significantly lower in these patients than that in the non-polypharmacy group.105) PIMs, as assessed by the 2015 American Geriatrics Society Beers Criteria, showed an independent negative association with ADL recovery in older patients undergoing convalescent rehabilitation after stroke.106) Furthermore, among those taking PIMs, patients using antipsychotics had lower ADL at admission and discharge, lower improvement in ADL with rehabilitation, and required longer rehabilitation times compared with those not taking antipsychotics.106) These findings demonstrate that polypharmacy and PIMs may worsen ADL in older adults requiring rehabilitation.

Some drugs may be positively associated with improvements in ADL. Statins have been shown to have both positive and negative effects on the physical function of older adults.106–108) Older patients taking allopurinol who underwent convalescent rehabilitation showed greater improvement in ADL than those not taking allopurinol.109) A recent systematic review found that the use of SSRIs in stroke patients with anxiety and depression improved ADL independence, disability, and neurological impairment.110) In contrast, however, another systematic review reported that the use of SSRIs in stroke patients without anxiety or depression was not effective in improving physical function.111) Future studies are needed to examine the effects of drug interventions on the recovery of physical function and ADL in older patients undergoing rehabilitation.

Cognitive Level

Medications, drug–drug interactions, and medication side effects can have a significant impact on arousal and the state of consciousness, leading to decreased cognitive levels. Drug-induced depression and drowsiness reduce cognitive levels. Polypharmacy, increased use of psychotropic drugs, and increased anticholinergic load impair the improvement of cognitive function in patients undergoing rehabilitation.52,55) Among anticholinergics, chlorpromazine and hydroxyzine have strong anticholinergic effects and may cause drug-induced cognitive impairment. Indeed, increased anticholinergic effects reduce improvements in comprehension and memory, which are cognitive components of ADL in convalescent rehabilitation.52) Dose reduction or discontinuation of the drug should be considered in patients with suspected drug-induced cognitive impairment. Encephalopathy may develop or become irreversible with prolonged use; however, discontinuation of the causative agent often results in improvement. Although some drugs such as cilostazol and citicoline are expected to be effective in preventing or improving cognitive decline in rehabilitation patients,112,113) there is still insufficient evidence in this regard. Therefore, future research is needed to provide clearer evidence of the beneficial effects of pharmacotherapy on cognitive function in patients undergoing rehabilitation.

Nutritional Status

Medication is one of the factors that affect the nutritional status of older adults undergoing rehabilitation. Polypharmacy and malnutrition increase with age and multimorbidity, and their relationship is based on several mechanisms.114) Indeed, malnutrition is found in 14%–65% of rehabilitation patients and hinders rehabilitation outcomes such as improvement in ADL and dysphagia, length of hospital stay, and home discharge rate.115–117) Moreover, excessive polypharmacy (more than 10 drugs) is associated with an increased risk of malnutrition after 3 years in people older than 75 years.118) Polypharmacy is also reportedly associated with

Copyright © 2022 The Japanese Association of Rehabilitation Medicine
sarcopenia,\textsuperscript{119} which occurs frequently in rehabilitation patients and is an independent predictor of worse rehabilitation outcomes.\textsuperscript{120–122} Recently, deprescribing polypharmacy in older sarcopenic patients undergoing convalescent rehabilitation was found to improve nutritional intake.\textsuperscript{104} Therefore, the prevention and correction of polypharmacy may lead to improvements in malnutrition.\textsuperscript{15} sarcopenia, and physical function in older adults.

Many clinically important drugs that can affect nutritional status cause anorexia. These include the following: (1) nonsteroidal anti-inflammatory drugs, corticosteroids, bisphosphonates, and potassium preparations that cause mucosal damage in the gastrointestinal tract; (2) opioids, anticancer drugs, and digitalis that cause nausea and vomiting; and (3) antihypertensive drugs, peptic ulcer drugs, antidepressants, antibiotics, and anticancer drugs that cause taste disorders.\textsuperscript{123}

PIMs are associated with a number of clinical risks such as drug–drug and drug–disease interactions, leading to an increased risk of malnutrition. Increased PIM use during convalescent hospitalization was negatively associated with improved nutritional status and decreased ADL improvement\textsuperscript{36}; benzodiazepine hypnotics, antipsychotics, and first-generation antihistamines were the most frequently used among these PIMs. The side effects of these drugs include dry mouth, extrapyramidal symptoms, and muscle relaxation. Therefore, nutritional intake may have been affected by side effects such as impaired lump formation, mouth opening and closing, and tongue movement, and dysphagia.

Another point worth discussing regarding the combination of pharmacotherapy and nutritional management is the Medication Pass Nutrition Supplement Program (Med-Pass).\textsuperscript{124} Med-Pass suggests distributing small (60 ml) calorie-dense oral nutritional supplements (ONS) three to four times a day between meals and at the time of medication administration. This strategy avoids duplication by using existing systems, prevents malnourished patients from taking supplements instead of meals, and may promote weight gain. Med-Pass, or prescribing sip feed ONS for taking medication, increases energy and protein intake and reduces weight loss during hospital stay.\textsuperscript{125,126} Thus, medication and nutritional management strategies such as Med-Pass may help address malnutrition related to polypharmacy and PIM.

**ROLE OF PHARMACISTS IN REHABILITATION MEDICINE**

The role of pharmacists in the healthcare system has expanded from dispensing services to direct patient care. The perspectives of pharmacists are essential in rehabilitation medicine. ADL assessment in older adults is effective in reducing ADEs\textsuperscript{127} and prescription review and pharmacological management by pharmacists can reduce the number of prescriptions, healthcare costs, and the frequency of drug-related problems.\textsuperscript{128–130} For inpatients undergoing rehabilitation, it is important for pharmacists to monitor ADL such as eating, exercise, toileting, cognition, and sleep while monitoring the patient’s vital signs and laboratory data for systemic management. While assessing patients’ ADL, pharmacists’ recommendations for appropriate drug prescriptions and optimization and deprescribing of polypharmacy and PIM may have a positive impact on rehabilitation outcomes. Rehabilitation is carried out by a multidisciplinary team of physicians, therapists, nurses, dietitians, and dental hygienists; however, the effects of drugs are often overlooked by professionals other than pharmacists. In patients undergoing rehabilitation, pharmacist-centered pharmacotherapy is necessary to enhance patients’ life functions from the perspective of “rehabilitation pharmacotherapy” and to minimize drug-induced functional impairment.\textsuperscript{131} In addition to older adults, the target population for pharmacist-centered pharmacotherapy should include all age groups that require rehabilitation. When initiating pharmacotherapy, goal setting should be aimed at maximizing the improvement of ADL and QOL of the target patients, in addition to optimizing pharmacotherapy.

Pharmacists are expected to provide patient care through a multidisciplinary team approach. The nutritional support team (NST) aims to improve ADL and dysphagia during the convalescent rehabilitation of stroke patients.\textsuperscript{132} Pharmacists are key members of the NST and share information on drug-related nutritional disorders through NST rounds and discussions; they also provide pharmacological and intravenous nutritional therapies that improve the quality of nutritional care.

Here, we propose a role for pharmacists in rehabilitation medicine for each of the following three stages: at the time of hospitalization, during the hospitalization period, and at the time of discharge; we focus on convalescent rehabilitation, which is an important setting for rehabilitation medicine (Fig. 1).

**At the Time of Hospital Admission**

When a patient is admitted, pharmacists should review all information regarding the number of prescribing physicians and hospitals, medication management practices, and adherence prior to hospitalization; they should also evaluate any
prior history of medication-related problems. In the acute phase, all comorbidities as well as the primary disease that led to the hospitalization should be reviewed, and drugs that can be reduced or discontinued should be identified; it is also important to ensure that all necessary drugs are being prescribed. During the convalescent and chronic phases, after the acute phase treatment is completed, all prescriptions should be reviewed to identify/evaluate the following: drugs that may no longer be needed at that time, acute phase drugs that should be continued, the appropriateness of drug doses, and any necessary drugs that have not been included. Drugs that can be tapered or discontinued during rehabilitation should also be listed. It is also important to provide relevant information to physicians and other professionals if some of the prescribed drugs that are difficult to reduce/discontinue may affect rehabilitation. The appropriate time to review all prescriptions is during transitions in care, such as that from acute care to convalescent care or from convalescent care to home or chronic care.

**During Hospitalization**

During hospitalization, patients are generally prescribed multiple medications. In addition to regular oral medications for the treatment of existing and primary diseases, the introduction of medications for patient complaints and functional disorders can easily increase the risk of polypharmacy. As patients’ ADL changes significantly (and in most cases improves) as rehabilitation progresses, drug prescriptions should be reviewed periodically and opportunistically according to the ADL at that time. Considerations for pharmacotherapy include checking whether a drug is limiting activity or participation, whether the requirement for the drug has changed due to improved or increased activity or participation, and whether any appropriate non-pharmacological treatments can be applied. Pharmacists should address polypharmacy by discussing and organizing the results of prescription reviews with physicians and other professionals. If there is a risk of adverse drug reactions, the symptoms and physical dysfunction of concern should be shared with the other professionals. After the prescription is discontinued or reduced, pharmacists should follow up carefully to determine if there are any subsequent changes in the patient’s condition. To assess patients’ ADL, pharmacists should collect information from medical records and other professionals and visit the wards to personally check the patients’ conditions. Locations for medication instruction and education for patients and their families include not only the bedside, but sometimes the training room or dining room also.
At the Time of Hospital Discharge

At the time of discharge, the prescription list should be reviewed once again according to the place of care. Drugs that may no longer be needed because of changes in the environment resulting from home discharge or institutionalization should be identified, and dose reduction or discontinuation should be considered for drugs that have a high risk of ADEs. During hospitalization, adherence is assured by the intervention of medical professionals; however, after discharge, there is a risk of decreased adherence and the development of new ADEs due to medication errors. Therefore, pharmacists should organize prescriptions with a focus on dosage (frequency and timing of taking the medication) to simplify medication management and reduce the burden of nursing care. After patient discharge, to ensure the coordination of pharmacotherapy, information should be provided to prescribers and pharmacists about the patient’s progress during hospitalization and the results of prescribing interventions using tools such as drug management summaries.

CONCLUSION

This review discusses the importance of pharmacotherapy in rehabilitation medicine with a focus on pathophysiology, epidemiology, drug-related problems, and ADL decline. Recommendations on the role of pharmacists in rehabilitation medicine are also presented. Older adults undergoing rehabilitation are affected by polypharmacy, PIMs, and anticholinergics, which can limit improvements in ADL and QOL. Therefore, pharmacist-centered multidisciplinary rehabilitation pharmacotherapy is recommended. However, few studies have focused on pharmacotherapy in rehabilitation medicine. Further research on rehabilitation pharmacotherapy is required to maximize patients’ physical function, activity, participation, and QOL.

CONFLICTS OF INTEREST

The authors report no conflicts of interest.

REFERENCES

1. Onder G, Marengoni A: Polypharmacy. JAMA 2017;318:1728. DOI:10.1001/jama.2017.15764, PMID:29114834

2. Calderón-Larrañaga A, Poblador-Plou B, González-Rubio F, Gimeno-Feliu LA, Abad-Diez JM, Prados-Torres A: Multimorbidity, polypharmacy, referrals, and adverse drug events: are we doing things well? Br J Gen Pract 2012;62:e821–e826. DOI:10.3399/bjgp12X659295, PMID:23211262

3. Fried TR, O’Leary J, Towe V, Goldstein MK, Trentalange M, Martin DK: Health outcomes associated with polypharmacy in community-dwelling older adults: a systematic review. J Am Geriatr Soc 2014;62:2261–2277. DOI:10.1111/jgs.13153, PMID:25516023

4. Motter FR, Fritzen JS, Hilmer SN, Paniz ÉV, Paniz VM: Potentially inappropriate medication in the elderly: a systematic review of validated explicit criteria. Eur J Clin Pharmacol 2018;74:679–700. DOI:10.1007/s00228-018-2446-0, PMID:29589066

5. Hamilton H, Gallagher P, Ryan C, Byrne S, O’Mahony D: Potentially inappropriate medications defined by STOPP criteria and the risk of adverse drug events in older hospitalized patients. Arch Intern Med 2011;171:1013–1019. DOI:10.1001/archinternmed.2011.215, PMID:21670370

6. The 2019 American Geriatrics Society Beers Criteria® Update Expert Panel: American Geriatrics Society 2019 Updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2019;67:674–694. DOI:10.1111/jgs.15767, PMID:30693946

7. Scales DC, Fischer HD, Li P, Bierman AS, Fernandes O, Mamdani M, Rochon P, Urbach DR, Bell CM: Unintentional continuation of medications intended for acute illness after hospital discharge: a population-based cohort study. J Gen Intern Med 2016;31:196–202. DOI:10.1007/s11606-015-3501-5, PMID:26369941

8. Gamble JM, Hall JJ, Marrie TJ, Sadowski CA, Majumdar SR, Eurich DT: Medication transitions and polypharmacy in older adults following acute care. Ther Clin Risk Manag 2014;10:189–196. PMID:24672243

9. Mixon AS, Neal E, Bell S, Powers JS, Kripalani S: Care transitions: a leverage point for safe and effective medication use in older adults – a mini-review. Gerontology 2015;61:32–40. DOI:10.1159/000363765, PMID:25277280

10. Kose E, Toyoshima M, Okazoe S, Oka R, Shiratsuchi Y, Hayashi H: The relationship between polypharmacy and recovery of activities of daily living among convalescent stroke patients: a propensity score-matched analysis. Eur Geriatr Med 2017;8:250–255. DOI:10.1016/j.eurger.2017.04.009
11. Maki H, Wakabayashi H, Nakamichi M, Momasaki R: Impact of the number of drug types on activities of daily living and length of hospital stay in patients with vertebral compression fractures on acute care hospitals. J Jpn Assoc Rehabil Nutr 2021;5:191–200.

12. Bachmann M, Kool J, Oesch P, Weber M, Bachmann S: Association of potentially inappropriate medications with outcomes of inpatient geriatric rehabilitation: a prospective cohort study. J Gerontol 2018;51:813–820. DOI:10.1007/s00391-017-1328-x, PMID:32725880

13. Yamaoka M, Chono M, Fukumoto M, Watanabe T, Fukaya T, Momasaki R: Impact of number of drugs on rehabilitation outcomes in patients after traumatic brain injury: a retrospective cohort study. PM R 2021;13:496–502. DOI:10.1002/pmrj.12460, PMID:32725880

14. Kose E, Hirai T, Seki T: Clinical factors affecting potentially inappropriate medications at discharge in older stroke patients. Eur Geriatr Med 2018;9:161–168. DOI:10.1007/s41999-018-0044-4, PMID:34654267

15. Kose E, Hirai T, Seki T: Change in number of potentially inappropriate medications impacts on the nutritional status in a convalescent rehabilitation setting. Geriatr Gerontol Int 2019;19:44–50. DOI:10.1111/ggi.13561, PMID:30488538

16. Clarke CL, Witham MD: The effects of medication on activity and rehabilitation of older people – opportunities and risks. Rehabil Process Outcome 2017;6:1–7.

17. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE: What is polypharmacy? A systematic review of definitions. BMC Geriatr 2017;17:230. DOI:10.1186/s12877-017-0621-2, PMID:29071479

18. Jokanovic N, Tan EC, Dooley MJ, Kirkpatrick CM, Bell JS: Prevalence and factors associated with polypharmacy in long-term care facilities: a systematic review. J Am Med Dir Assoc 2015;16:535.e1–535.e12. DOI:10.1016/j.jamda.2015.03.003, PMID:25869992

19. Maher RL, Hanlon J, Hajjar ER: Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf 2014;13:57–65. DOI:10.1517/14740338.2013.827660, PMID:24073682

20. Jyrkkä J, Enlund H, Korhonen MJ, Sulkava R, Hartikainen S: Polypharmacy status as an indicator of mortality in an elderly population. Drugs Aging 2009;26:1039–1048. DOI:10.2165/11319530-000000000-00000, PMID:19929031

21. Hilmer SN, Gnjidic D: The effects of polypharmacy in older adults. Clin Pharmacol Ther 2009;85:86–88. DOI:10.1038/clpt.2008.224, PMID:19037203

22. Rochon PA, Gurwitz JH: Optimising drug treatment for elderly people: the prescribing cascade. BMJ 1997;315:1096–1099. DOI:10.1136/bmj.315.7115.1096, PMID:9366745

23. Brath H, Mehta N, Savage RD, Gill SS, Wur W, Bronskill SE, Zhu L, Gurwitz JH, Rochon PA: What is known about preventing, detecting, and reversing prescribing cascades: a scoping review. J Am Geriatr Soc 2018;66:2079–2085. DOI:10.1111/jgs.15543, PMID:30335185

24. Kojima T, Akishita M, Kameyama Y, Yamaguchi K, Yamamoto H, Eto M, Ouchi Y: High risk of adverse drug reactions in elderly patients taking six or more drugs: analysis of inpatient database. Geriatr Gerontol Int 2012;12:761–762. DOI:10.1111/j.1447-0594.2012.00868.x, PMID:22998384

25. O’Connor MN, Gallagher P, O’Mahony D: Inappropriate prescribing: criteria, detection and prevention. Drugs Aging 2012;29:437–452. DOI:10.2165/11632610-000000000-00000, PMID:22642779

26. Spinewine A, Schmader KE, Barber N, Hughes C, Lapane KL, Swine C, Hanlon JT: Appropriate prescribing in elderly people: how well can it be measured and optimised? Lancet 2007;370:173–184. DOI:10.1016/S0140-6736(07)61091-5, PMID:17630041

27. O’Mahony D: STOPP/START criteria for potentially inappropriate medications/potential prescribing omissions in older people: origin and progress. Expert Rev Clin Pharmacol 2020;13:15–22. DOI:10.1080/17512433.2020.1697676, PMID:31790317

28. Kojima T, Mizukami K, Tomita N, Arai H, Ohruji T, Eto M, Takeya Y, Isaka Y, Rakugi H, Sudo N, Arai H, Aoki H, Horie S, Ishii S, Iwasaki K, Takayama S, Suzuki Y, Matsui T, Mizokami F, Furuta K, Toba K, Akishita M, Working Group on Guidelines for Medical Treatment and its Safety in the Elderly: Screening tool for older persons’ appropriate prescriptions for Japanese: report of the Japan Geriatrics Society Working Group on “Guidelines for medical treatment and its safety in the elderly”. Geriatr Gerontol Int 2016;16:983–1001. DOI:10.1111/ggi.12890, PMID:27594406
29. Saarelainen LK, Turner JP, Shakib S, Singhal N, Hogan-Doran J, Prowse R, Johns S, Lees J, Bell JS: Potentially inappropriate medication use in older people with cancer: prevalence and correlates. J Geriatr Oncol 2014;5:439–446. DOI:10.1016/j.jgo.2014.07.001, PMID:25127252
30. Karuturi MS, Holmes HM, Lei X, Johnson M, Barcenas CH, Cantor SB, Gallick GE, Bast RC Jr, Giordano SH: Potentially inappropriate medication use in older patients with breast and colorectal cancer. Cancer 2018;124:3000–3007. DOI:10.1002/cncr.31403, PMID:29692396
31. Cadogan CA, Ryan C, Hughes CM: Appropriate polypharmacy and medicine safety: when many is not too many. Drug Saf 2016;39:109–116. DOI:10.1007/s40266-015-0378-5, PMID:26692396
32. Fabbietti P, Ruggiero C, Sganga F, Fusco S, Mammarella F, Barbini N, Cassetta L, Onder G, Corsonello A, Lattanzio F, Di Rosa M: Effects of hyperpolypharmacy and potentially inappropriate medications (PIMs) on functional decline in older patients discharged from acute care hospitals. Arch Gerontol Geriatr 2018;77:158–162. DOI:10.1016/j.archger.2018.05.007, PMID:30429122
33. Nagai T, Wakabayashi H, Maeda K, Momosaki R, Nishiyama A, Murata H, Uei H: Influence of potentially inappropriate medications on activities of daily living for patients with osteoporotic vertebral compression fractures: a retrospective cohort study. J Orthop Sci 2021;26:448–452. DOI:10.1016/j.jos.2020.03.015, PMID:32307184
34. Nakamichi M, Wakabayashi H, Nishioka S, Momosaki R: Influence of antipsychotics on functional prognosis after geriatric hip fracture. J Nutr Health Aging 2019;23:381–385. DOI:10.1007/s12603-019-1173-2, PMID:30932138
35. Iaboni A, Rawson K, Burkett C, Lenze EJ, Flint AJ: Potentially inappropriate medications and the time to full functional recovery after hip fracture. Drugs Aging 2017;34:723–728. DOI:10.1007/s40266-017-0482-6, PMID:28776209
36. Kose E, Hirai T, Seki T, Hayashi H: Role of potentially inappropriate medication use in rehabilitation outcomes for geriatric patients after strokes. Geriatr Gerontol Int 2018;18:321–328. DOI:10.1111/ggi.13187, PMID:29105246
37. Masumoto S, Sato M, Maeno T, Ichinohe Y, Maeno T: Association between potentially inappropriate medications and anxiety in Japanese older patients. Geriatr Gerontol Int 2017;17:2520–2526. DOI:10.1111/ggi.13128, PMID:28858424
38. Komagamine J, Yabuki T, Kobayashi M: Association between potentially inappropriate medications at discharge and unplanned readmissions among hospitalised elderly patients at a single centre in Japan: a prospective observational study. BMJ Open 2019;9:e032574. DOI:10.1136/bmjopen-2019-032574, PMID:31699748
39. Pérez T, Moriarty F, Wallace E, McDowell R, Redmond P, Fahey T: Prevalence of potentially inappropriate prescribing in older people in primary care and its association with hospital admission: longitudinal study. BMJ 2018;363:k4524. DOI:10.1136/bmj.k4524, PMID:30429122
40. Dalleur O, Spinewine A, Henrard S, Losseau C, Speybroeck N, Boland B: Inappropriate prescribing and related hospital admissions in frail older persons according to the STOPP and START criteria. Drugs Aging 2012;29:829–837. DOI:10.1007/s40266-012-0016-1, PMID:23044639
41. Frankenthal D, Lerman Y, Lerman Y: The impact of hospitalization on potentially inappropriate prescribing in an acute medical geriatric division. Int J Clin Pharm 2015;37:60–67. DOI:10.1007/s11996-014-0040-9, PMID:25428445
42. Higashi T, Shekelle PG, Solomon DH, Knight EL, Roth C, Chang JT, Kamberg CJ, MacLean CH, Young RT, Adams J, Reuben DB, Avorn J, Wenger NS: The quality of pharmacologic care for vulnerable older patients. Ann Intern Med 2004;140:714–720. DOI:10.7326/0003-4819-140-9-200405040-00011, PMID:15126255
43. Kuijpers MA, van Marum RJ, Egberts AC, Jansen PA, OLDY (OLd people Drugs & dYsregulations) Study Group: Relationship between polypharmacy and underprescribing. Br J Clin Pharmacol 2008;65:130–133. DOI:10.1111/j.1365-2125.2007.02961.x, PMID:17578478
44. Kuzuya M, Masuda Y, Hirakawa Y, Iwata M, Enoki H, Hasegawa J, Cheng XW, Iguchi A: Underuse of medications for chronic diseases in the oldest of community-dwelling older frail Japanese. J Am Geriatr Soc 2006;54:598–605. DOI:10.1111/j.1532-5415.2006.00659.x, PMID:16686869
45. Fox C, Smith T, Maidment I, Chan WY, Bua N, Myint PK, Boustani M, Kwok CS, Glover M, Koopmans I, Campbell N: Effect of medications with anti-cholinergic properties on cognitive function, delirium, physical function and mortality: a systematic review. Age Ageing 2014;43:604–615. DOI:10.1093/ageing/afu096, PMID:25038833

46. Mintzer J, Burns A: Anticholinergic side-effects of drugs in elderly people. J R Soc Med 2000;93:457–462. DOI:10.1177/014107680009300903, PMID:11089480

47. Blazer DG 2nd, Federspiel CF, Ray WA, Schaffner W: The risk of anticholinergic toxicity in the elderly: a study of prescribing practices in two populations. J Gerontol 1983;38:31–35. DOI:10.1093/geronj/38.1.31, PMID:6129272

48. Salahudeen MS, Duffull SB, Nishtala PS: Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review. BMC Geriatr 2015;15:31. DOI:10.1186/s12877-015-0029-9, PMID:25879993

49. Gnjidic D, Bell JS, Hilmer SN, Lönnroos E, Sulkava R, Hartikainen S: Drug burden index associated with function in community-dwelling older people in Finland: a cross-sectional study. Ann Med 2012;44:458–467. DOI:10.3109/07853890.2011.573499, PMID:21495785

50. Collamati A, Martone AM, Poscia A, Brandi V, Celi M, Marzetti E, Cherubini A, Landi F: Anticholinergic drugs and negative outcomes in the older population: from biological plausibility to clinical evidence. Aging Clin Exp Res 2016;28:25–35. DOI:10.1007/s40520-015-0359-7, PMID:25930085

51. Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE: The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med 2008;168:508–513. DOI:10.1001/archinternmed.2007.106, PMID:18332297

52. Kose E, Hirai T, Seki T, Hidaka S, Hamamoto T: Anticholinergic load negatively correlates with recovery of cognitive activities of daily living for geriatric patients after stroke in the convalescent stage. J Clin Pharm Ther 2018;43:799–806. DOI:10.1111/jcpt.12706, PMID:29770467

53. Nissan R, Brill S, Hershkovitz A: Association between anticholinergic drug prescription changes and rehabilitation outcome in post-acute hip fractured patients. Disabil Rehabil 2020;42:2917–2922. DOI:10.1080/09638882.2019.1576782, PMID:30978127

54. Hershkovitz A, Angel C, Brill S, Nissan R: The association between anticholinergic drug use and rehabilitation outcome in post-acute hip fractured patients: a retrospective cohort study. Drugs Aging 2018;35:333–341. DOI:10.1007/s40266-018-0533-7, PMID:29500684

55. Kose E, Hirai T, Seki T: Psychotropic drug use and cognitive rehabilitation practice for elderly patients. Int J Clin Pharm 2018; 40: 1292–1299. DOI:10.1007/s11096-018-0718-5, PMID:30132235

56. Stoschus B, Allescher HD: Drug-induced dysphagia. Dysphagia 1993;8:154–159. DOI:10.1007/BF02266997, PMID:8467724

57. Schwemmlle C, Jungheim M, Miller S, Kühn D, Ptok M: Medikamenteninduzierte Dysphagien. HNO 2015;63:504–510. DOI:10.1007/s00106-015-0015-8, PMID:26148562

58. Kose E, Hirai T, Seki T: Assessment of aspiration pneumonia using the anticholinergic risk scale. Geriatr Gerontol Int 2018;18:1230–1235. DOI:10.1111/gerg.13454, PMID:29856113

59. Wada H, Nakajoh K, Satoh-Nakagawa T, Suzuki T, Ohru T, Arahi H, Sasaki H: Risk factors of aspiration pneumonia in Alzheimer's disease patients. Gerontology 2001;47:271–276. DOI:10.1159/000052811, PMID:11490146

60. Sun G, Zhang L, Zhang L, Wu Z, Hu D: Benzodiazepines or related drugs and risk of pneumonia: a systematic review and meta-analysis. Int J Geriatr Psychiatry 2019;34:513–521. DOI:10.1002/gps.5048, PMID:30623504

61. Yamaya M, Yanai M, Ohru T, Arahi H, Sasaki H: Interventions to prevent pneumonia among older adults. J Am Geriatr Soc 2001;49:85–90. DOI:10.1046/j.1532-5415.2001.49015.x, PMID:11207848

62. Arahi T, Yasuda Y, Toshima S, Yoshimi N, Kashiki Y: ACE inhibitors and pneumonia in elderly people. Lancet 1998;352:1937–1938. DOI:10.1016/S0140-6736(05)60437-0, PMID:9863819

63. Nakagawa T, Wada H, Sekizawa K, Arahi H, Sasaki H: Amantadine and pneumonia. Lancet 1999;353:1157. DOI:10.1016/S0140-6736(98)05805-X, PMID:10209989

64. Teramoto S, Yamamoto H, Yamaguchi Y, Ishii M, Hibi S, Kume H, Ouchi Y: Antiplatelet cilostazol, an inhibitor of type III phosphodiesterase, improves swallowing function in patients with a history of stroke. J Am Geriatr Soc 2008;56:1153–1154. DOI:10.1111/j.1532-5415.2008.01703.x, PMID:18554369
65. Iwasaki K, Wang Q, Nakagawa T, Suzuki T, Sasaki H: The traditional Chinese medicine banxia houpo tang improves swallowing reflex. Phytomedicine 1999;6:103–106. DOI:10.1016/S0944-7113(99)80043-9, PMID:10374248

66. Iwasaki K, Cyong JC, Kitada S, Kitamura H, Ozeki J, Satoh Y, Suzuki T, Sasaki H: A traditional Chinese herbal medicine, banxia houpo tang, improves cough reflex of patients with aspiration pneumonia. J Am Geriatr Soc 2002;50:1751–1752. DOI:10.1046/j.1532-5415.2002.50479.x, PMID:12366640

67. Warrington TP, Bostwick JM: Psychiatric adverse effects of corticosteroids. Mayo Clin Proc 2006;81:1361–1367. DOI:10.4065/81.10.1361, PMID:17036562

68. Ganzini L, Walsh JR, Millar SB: Drug-induced depression in the aged. What can be done? Drugs Aging 1993;3:147–158. DOI:10.2165/00002512-199303020-00005, PMID:8477147

69. Van Gastel A: Drug-induced insomnia and excessive sleepiness. Sleep Med Clin 2018;13:147–159. DOI:10.1016/j.jsmc.2018.02.001, PMID:29759266

70. Remick RA: Anticholinergic side effects of tricyclic antidepressants and their management. Prog Neuro-psychopharmacol Biol Psychiatry 1988;12:225–231. DOI:10.1016/0278-5846(88)90039-5, PMID:2909996

71. Jiang HY, Chen HZ, Hu XJ, Yu ZH, Yang W, Deng M, Zhang YH, Ruan B: Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2015;13:42–50.e3. DOI:10.1016/j.cgh.2014.06.021, PMID:24993365

72. Wichniak A, Wierzbicka A, Walęcka M, Jernajczyk W: Effects of antidepressants on sleep. Curr Psychiatry Rep 2017;19:63. DOI:10.1007/s11920-017-0816-4, PMID:28791566

73. Bergen G, Stevens MR, Burns ER: Falls and fall injuries among adults aged ≥65 years — United States, 2014. MMWR Morb Mortal Wkly Rep 2016;65:993–998. DOI:10.15585/mmwr.mm6537a2, PMID:27656914

74. Ganz DA, Bao Y, Shekelle PG, Rubenstein LZ: Will my patient fall? JAMA 2007;297:77–86. DOI:10.1001/jama.297.1.77, PMID:17020478

75. Kelsey JL, Procter-Gray E, Hannan MT, Li W: Heterogeneity of falls among older adults: implications for public health prevention. Am J Public Health 2012;102:2149–2156. DOI:10.2105/AJPH.2012.300677, PMID:22994167

76. Zhang X, Huang P, Dou Q, Wang C, Zhang W, Yang Y, et al.: Falls among older adults with sarcopenia dwelling in nursing home or community: a meta-analysis. Clinical Nutr 2020;39:33–39. DOI:10.1016/j.clnu.2019.01.002

77. Muir SW, Berg K, Chesworth B, Klari N, Speechley M: Quantifying the magnitude of risk for balance impairment on falls in community-dwelling older adults: a systematic review and meta-analysis. J Clin Epidemiol 2010;63:389–406. DOI:10.1016/j.jclinepi.2009.06.010, PMID:19744824

78. Deandaera S, Lucenteforte E, Bravi F, Foschi R, La Vecchia C, Negri E: Risk factors for falls in community-dwelling older people: a systematic review and meta-analysis. Epidemiology 2010;21:658–668. DOI:10.1097/ EDE.0b013e3181e89905, PMID:20585256

79. Mol A, Bui Hoang PT, Sharmin S, Reijnierse EM, van Wezel RJ, Meskers CG, Maier AB: Orthostatic hypotension and falls in older adults: a systematic review and meta-analysis. J Am Med Dir Assoc 2019;20:589–597. e5. DOI:10.1016/j.jamda.2018.11.003, PMID:30538399

80. de Vries M, Seppala LJ, Daams JG, van de Giemd EM, Masud T, van der Velde N, Blain H, Bousquet J, Bucht G, Caballero-Mora MA, van der Cammen T, Eklund P, Emmelot-Vonk M, Gustafson Y, Hartikainen S, Kenny RA, Laflamme L, Landi F, Masud T, O’Byrne-Maguire I, Petrovic M, Rodriguez L, Seppälä L, Svensson O, Szczerbińska K, Thaler H, van der Velde N, EUGMS Task and Finish Group on Fall-Risk-Increasing Drugs: Fall-risk-increasing drugs: a systematic review and meta-analysis: I. Cardiovascular drugs. J Am Med Dir Assoc 2018;19:371.e1–371.e9. DOI:10.1016/j.jamda.2017.12.013, PMID:29396189

81. Seppala LJ, Wermelink AM, de Vries M, Ploegmakers KJ, van de Giemd EM, Daams JG, van der Velde N, Blain H, Bousquet J, Bucht G, Caballero-Mora MA, van der Cammen T, Eklund P, Emmelot-Vonk M, Gustafson Y, Hartikainen S, Kenny RA, Laflamme L, Landi F, Masud T, O’Byrne-Maguire I, Petrovic M, Rodriguez L, Seppälä L, Svensson O, Szczerbińska K, Thaler H, van der Velde N, EUGMS Task and Finish Group on Fall-Risk-Increasing Drugs: Fall-risk-increasing drugs: a systematic review and meta-analysis: II. Psychotropics. J Am Med Dir Assoc 2018;19:371.e11–371.e17. DOI:10.1016/j.jamda.2017.12.098, PMID:29402652

Copyright © 2022 The Japanese Association of Rehabilitation Medicine
82. Campbell AJ: Drug treatment as a cause of falls in old age. A review of the offending agents. Drugs Aging 1991;1:289–302. DOI:10.2165/00002512-199101040-00005, PMID:1794021
83. Madoff RD, Parker SC, Varma MG, Lowry AC: Faecal incontinence in adults. Lancet 2004;364:621–632. DOI:10.1016/S0140-6736(04)66856-6, PMID:15313364
84. Rodriguez-Ramallo H, Báez-Gutiérrez N, Prado-Mel E, Alfaro-Lara ER, Santos-Ramos B, Sánchez-Fidalgo S: Association between Anticholinergic Burden and Constipation: A Systematic Review. Healthcare (Basel, Switzerland). 2021; 9.
85. Tello L, Perez-Freytes R: Fluid and electrolyte therapy during vomiting and diarrhea. Vet Clin North Am Small Anim Pract 2017;47:505–519. DOI:10.1016/j.cvsm.2016.09.013, PMID:27939861
86. Irwin GM: Urinary incontinence. Prim Care Clin Off Pract 2019;46:233–242. DOI:10.1016/j.pop.2019.02.004, PMID:31030824
87. Sussman RD, Syan R, Brucker BM: Guideline of guidelines: urinary incontinence in women. BJU Int 2020;125:638–655. DOI:10.1111/bju.14927
88. Resnick NM, Yalla SV: Management of urinary incontinence in the elderly. N Engl J Med 1985;313:800–805. DOI:10.1056/NEJM198509263131307, PMID:2863753
89. Mallinson T, Fitzgerald CM, Neville CE, Almagor O, Manheim L, Deutsch A, Heinemann A: Impact of urinary incontinence on medical rehabilitation inpatients. Neurourol Urodyn 2017;36:176–183. DOI:10.1002/nau.22908, PMID:26473408
90. Tune LE: Anticholinergic effects of medication in elderly patients. J Clin Psychiatry 2001;62(Suppl 21):11–14. PMID:11584981
91. Leong RW, Chan FK: Drug-induced side effects affecting the gastrointestinal tract. Expert Opin Drug Saf 2006;5:585–592. DOI:10.1517/14740338.5.4.585, PMID:16774495
92. Imam MZ, Kuo A, Ghassabian S, Smith MT: Progress in understanding mechanisms of opioid-induced gastrointestinal adverse effects and respiratory depression. Neuropharmacology 2018;131:238–255. DOI:10.1016/j.neuropharm.2017.12.032, PMID:29273520
93. Tolkin Z, Stecher L, Mander AP, Pereira DI, Powell JJ: Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. PLoS One 2015;10:e0117383. DOI:10.1371/journal.pone.0117383, PMID:25700159
94. Aapro M, Scotté F, Escobar Y, Celio L, Berman R, Franceschetti A, Bell D, Jordan K: Practice patterns for prevention of chemotherapy-induced nausea and vomiting and antiemetic guideline adherence based on real-world prescribing data. Oncologist 2021;26:e1073–e1082. DOI:10.1002/ongo.13716, PMID:33555084
95. Malihi Z, Wu Z, Stewart AW, Lawes CM, Scragg R: Hypercalcemia, hypercalciuria, and kidney stones in long-term studies of vitamin D supplementation: a systematic review and meta-analysis. Am J Clin Nutr 2016;104:1039–1051. DOI:10.3945/ajcn.116.134981, PMID:27604776
96. Mori H, Tack J, Suzuki H: Magnesium oxide in constipation. Nutrients 2021;13:421. DOI:10.3390/nu13020421, PMID:33525523
97. Vandereycken W: Neuroleptics in the short-term treatment of anorexia nervosa. A double-blind placebo-controlled study with sulpiride. Br J Psychiatry 1984;144:288–292. DOI:10.1192/bjp.144.3.288, PMID:6367876
98. Nakae H, Hiroshima Y, Hebiguchi M: Kampo medicines for frailty in locomotor disease. Front Nutr 2018;5:31. DOI:10.3389/fnut.2018.00031, PMID:29755984
99. Yoshimura Y, Wakabayashi H, Nagano F, Bise T, Shimazu S, Shiraishi A: Low hemoglobin levels are associated with sarcopenia, dysphagia, and adverse rehabilitation outcomes after stroke. J Stroke Cerebrovasc Dis 2020;29:105405. DOI:10.1016/j.jstrokecerebrovasdis.2020.105405, PMID:33254381
100. Yoshimura Y, Wakabayashi H, Shiraishi A, Nagano F, Bise T, Shimazu S: Hemoglobin improvement is positively associated with functional outcomes in stroke patients with anemia. J Stroke Cerebrovasc Dis 2021;30:105453. DOI:10.1016/j.jstrokecerebrovasdis.2020.105453, PMID:33188950
101. Tay HS, Soiza RL: Systematic review and meta-analysis: what is the evidence for oral iron supplementation in treating anaemia in elderly people? Drugs Aging 2015;32:149–158. DOI:10.1007/s40266-015-0241-5, PMID:25644019
102. Thanvi B, Treadwell S: Drug induced parkinsonism: a common cause of parkinsonism in older people. Postgrad Med J 2009;85:322–326. DOI:10.1136/pgmj.2008.073312, PMID:19528308
103. Ahn HJ, Yoo WK, Park J, Ma HI, Kim YJ: Cognitive dysfunction in drug-induced parkinsonism caused by prokinetics and antiemetics. J Korean Med Sci 2015;30:1328–1333. DOI:10.3346/jkms.2015.30.9.1328, PMID:26339175

104. Matsumoto A, Yoshimura Y, Wakabayashi H, Kose E, Nagano F, Bise T, Kido Y, Shimazu S, Shiraishi A: Deprescribing leads to improved energy intake among hospitalized older sarcopenic adults with polypharmacy after stroke. Nutrients 2022;14:443. DOI:10.3390/nu14030443, PMID:35276802

105. Kose E, Maruyama R, Okazoe S, Hayashi H: Impact of polypharmacy on the rehabilitation outcome of Japanese stroke patients in the convalescent rehabilitation ward. J Aging Res 2016;2016:1–8. DOI:10.1155/2016/7957825, PMID:28042484

106. Hershkovitz A, Nissan R: The association between antipsychotic drug use and rehabilitation outcome in post-acute hip fractured patients: a retrospective cohort study. J Appl Gerontol 2021;40:661–669. DOI:10.1177/0733464820904564, PMID:32026744

107. Kawai H, Ihara K, Kera T, Hirano H, Fujiwara Y, Tanaka M, Kojima M, Obuchi S: Association between statin use and physical function among community-dwelling older Japanese adults. Geriatr Gerontol Int 2018;18:623–630. DOI:10.1111/ggi.13228, PMID:29278297

108. Li Y, Yang X, Zou Y, Li J, Sun Q, Jing X, Yang M, Wang S, Dong B: Association between statin use and physical function among older Chinese inpatients with type 2 diabetes. J Nutr Health Aging 2020;24:194–197. DOI:10.1007/s12603-019-1305-8, PMID:32003410

109. Beveridge LA, Ramage L, McMurdo ME, George J, Witham MD: Allopurinol use is associated with greater functional gains in older rehabilitation patients. Age Ageing 2013;42:400–404. DOI:10.1093/ageing/aft046, PMID:23542729

110. Legg LA, Rudberg AS, Hua X, Wu S, Hackett ML, Tilney R, Lindgren L, Kutlubayev MA, Hsieh CF, Barugh AJ, Hankey GJ, Lundstrom E, Dennis M, Mead GE: Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database Syst Rev 2021;11:CD009286. PMID:34780067

111. Legg LA, Tilney R, Hsieh CF, Wu S, Lundstrom E, Rudberg AS, Kutlubayev MA, Dennis M, Soleimani B, Barugh A, Hackett ML, Hankey GJ, Mead GE: Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database Syst Rev 2019;2019:CD009286. DOI:10.1002/14651858.CD009286.pub3, PMID:31769878

112. Senda J, Ito K, Kotake T, Kanamori M, Kishimoto H, Kadono I, Nakagawa-Senda H, Wakai K, Katsuno M, Nishida Y, Ishiguro N, Sobue G: Cilostazol use is associated with FIM cognitive improvement during convalescent rehabilitation in patients with ischemic stroke: a retrospective study. Nagoya J Med Sci 2019;81:359–373. PMID:31579328

113. Fioravanti M, Yanagi M: Cytidinediphosphocholine (CDP choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev 2004: CD000269.

114. Zadak Z, Hyspler R, Ticha A, Vlcek J: Polypharmacy and malnutrition. Curr Opin Clin Nutr Metab Care 2013;16:50–55. DOI:10.1097/MCO.0b013e32835b612e, PMID:23201650

115. Yoshimura Y, Wakabayashi H, Bise T, Tanoue M: Prevalence of sarcopenia and its association with activities of daily living and dysphagia in convalescent rehabilitation ward inpatients. Clin Nutr 2018;37(6 Pt A):2022–2028. DOI:10.1016/j.clnu.2017.09.009, PMID:28987469

116. Shiraishi A, Yoshimura Y, Wakabayashi H, Tsuji Y: Prevalence of stroke-related sarcopenia and its association with poor oral status in post-acute stroke patients: implications for oral sarcopenia. Clin Nutr 2018;37:204–207. DOI:10.1016/j.clnu.2016.12.002, PMID:28017450

117. Marshall S: Protein-energy malnutrition in the rehabilitation setting: evidence to improve identification. Maturitas 2016;86:77–85. DOI:10.1016/j.maturitas.2016.01.014, PMID:26921933

118. Jyrkkä J, Enlund H, Lavikainen P, Sulkava R, Hartikainen S: Association of polypharmacy with nutritional status, functional ability and cognitive capacity over a three-year period in an elderly population. Pharmacoepidemiol Drug Saf 2011;20:514–522. DOI:10.1002/pds.2116, PMID:21308855
119. Pana A, Sourtzi P, Kalokairinou A, Velonaki VS: Sarcopenia and polypharmacy among older adults: a scoping review of the literature. Arch Gerontol Geriatr 2022;98:104520. DOI:10.1016/j.archger.2021.104520, PMID:34619629

120. Yoshimura Y, Bise T, Nagano F, Shimazu S, Shiraishi A, Yamaga M, Koga H: Systemic inflammation in the recovery stage of stroke: its association with sarcopenia and poor functional rehabilitation outcomes. Prog Rehabil Med 2018;3: 1–10. DOI:10.2490/prm.20180011, PMID:32789236

121. Kido Y, Yoshimura Y, Wakabayashi H, Momosaki R, Nagano F, Bise T, Shimazu S, Shiraishi A: Sarcopenia is associated with incontinence and recovery of independence in urination and defecation in post-acute rehabilitation patients. Nutrition 2021;91-92:111397. DOI:10.1016/j.nut.2021.111397, PMID:34364264

122. Yoshimura Y, Wakabayashi H, Bise T, Nagano F, Shimazu S, Shiraishi A: Sarcopenia is associated with worse recovery of physical function and dysphagia and a lower rate of home discharge in Japanese hospitalized adults undergoing convalescent rehabilitation. Nutrition 2019;61:111–118. DOI:10.1016/j.nut.2019.01.005, PMID:30710883

123. Varma RN: Risk for drug-induced malnutrition is unchecked in elderly patients in nursing homes. J Am Diet Assoc 1994;94:192–194. DOI:10.1016/0002-8223(94)90247-X, PMID:8300997

124. Canadian Agency for Drugs and Technologies in Health. The medication pass nutritional supplement program in patients receiving medication: a review of clinical effectiveness and guidelines. CADTH Rapid Response Reports. 2015. https://www.ncbi.nlm.nih.gov/books/NBK304827/

125. Campbell KL, Webb L, Vivanti A, Varghese P, Ferguson M: Comparison of three interventions in the treatment of malnutrition in hospitalised older adults: a clinical trial. Nutr Diet 2013;70:325–331. DOI:10.1111/1747-0080.12008

126. Potter JM, Roberts MA, McColl JH, Reilly JJ: Protein energy supplements in unwell elderly patients – a randomized controlled trial. J Parenter Enter Nutr 2001;25:323–329. DOI:10.1177/0148607101025006323, PMID:11688936

127. Onder G, Lattanzio F, Battaglia M, Cerullo F, Sportiello R, Bernabei R, Landi F: The risk of adverse drug reactions in older patients: beyond drug metabolism. Curr Drug Metab 2011;12:647–651. DOI:10.2174/138920011796504563, PMID:21495971

128. Zermansky AG, Petty DR, Raynor DK, Lowe CJ, Freemantle N, Vail A: Clinical medication review by a pharmacist of patients on repeat prescriptions in general practice: a randomised controlled trial. Health Technol Assess 2002;6:1–86. DOI:10.3310/hta6200, PMID:12234455

129. Mekonnen AB, McLachlan AJ, Brien JE: Effectiveness of pharmacist-led medication reconciliation programmes on clinical outcomes at hospital transitions: a systematic review and meta-analysis. BMJ Open 2016;6:e010003. DOI:10.1136/bmjopen-2015-010003, PMID:26908524

130. Willoch K, Blix HS, Pedersen-Bjergaard AM, Eek AK, Reikvam A: Handling drug-related problems in rehabilitation patients: a randomized study. Int J Clin Pharm 2012;34:382–388. DOI:10.1007/s11096-012-9623-5, PMID:22386601

131. Wakabayashi H: Rehabilitation pharmacotherapy: a combination of rehabilitation and pharmacotherapy. J Gen Fam Med 2018;19:43–44. DOI:10.1002/jgf2.163, PMID:29600126

132. Shimazu S, Yoshimura Y, Kudo M, Nagano F, Bise T, Shiraishi A, Sunahara T: Frequent and personalized nutritional support leads to improved nutritional status, activities of daily living, and dysphagia after stroke. Nutrition 2021;83:111091. DOI:10.1016/j.nut.2021.111091, PMID:33388653

133. Pasina L, Brucato AL, Falcone C, Cucchi E, Bresciani A, Sottocorno M, Taddei GC, Casati M, Franchi C, Djaide CD, Nobili A: Medication non-adherence among elderly patients newly discharged and receiving polypharmacy. Drugs Aging 2014;31:283–289. DOI:10.1007/s40266-014-0163-7, PMID:24604085